Gilberto Lopes, Professor and Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“Alright. As promised.
Here is our preprint assessing the cost-effectiveness of daraxonrasib! Daraxonrasib nearly doubled median overall survival in previously treated metastatic pancreatic adenocarcinoma, in which median survival with standard chemotherapy was about 7 months, and should remain available to eligible patients.”
Title: Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma
Authors: Sunwoo Han, Natallia Starasvetskaya, Gretel Terrero, Peter Hosein, Gilberto de Lima Lopes Junior
You can also read: FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer
